These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6935936)

  • 1. Platelets intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thrombo-embolic complications.
    Carvalho AC; Lees RS
    Acta Med Scand Suppl; 1980; 642():101-12. PubMed ID: 6935936
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood coagulation and fibrinolysis systems in primary hyperlipoproteinemias].
    Berent H; Uchman B
    Pol Arch Med Wewn; 1983 Sep; 70(3):131-4. PubMed ID: 6657492
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 4. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thrombogenesis. Role of the thrombocytes, coagulation and fibrinolysis in thrombosis].
    Stoichiţă-Papilian M
    Stud Cercet Med Interna; 1972; 13(3):219-35. PubMed ID: 5070564
    [No Abstract]   [Full Text] [Related]  

  • 7. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogenesis of disseminated intravascular coagulation.
    Evensen SA; Hjort PF
    Hamatol Bluttransfus; 1970; 9():109-20. PubMed ID: 5508063
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia.
    Carvalho AC; Lees RS; Vaillancourt RA; Colman RW
    Circulation; 1977 Jul; 56(1):114-8. PubMed ID: 301067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome.
    Llach F
    Kidney Int; 1985 Sep; 28(3):429-39. PubMed ID: 3906225
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidaemia.
    Schmidt EB; Ernst E; Varming K; Pedersen JO; Dyerberg J
    Thromb Haemost; 1989 Sep; 62(2):797-801. PubMed ID: 2814927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of vitamin E on the changes in plasma lipid peroxides and platelet aggregation in patients with hyperlipoproteinemia].
    Dworski R; Domagała B; Hartwich J; Radwan J; Grzywacz M; Szczeklik A
    Pol Arch Med Wewn; 1986 Jun; 75(6):393-401. PubMed ID: 3808976
    [No Abstract]   [Full Text] [Related]  

  • 14. Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia.
    Smith CM; Burris SM; Hunninghake DB; White JG
    Am J Hematol; 1988 Apr; 27(4):247-52. PubMed ID: 3354559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects.
    Zucker ML; Bilyeu DS; Helmkamp GM; Harris WS; Dujovne CA
    Atherosclerosis; 1988 Sep; 73(1):13-22. PubMed ID: 3178928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differential use of diet and drugs in dyslipoproteinemias].
    Lipovetskiĭ BM; Triufanov VF; Teriukova NP
    Klin Med (Mosk); 1985 Jan; 63(1):116-20. PubMed ID: 3990175
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia.
    Muller S; Ziegler O; Donner M; Drouin P; Stoltz JF
    Atherosclerosis; 1990 Aug; 83(2-3):231-7. PubMed ID: 2242099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 20. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.